These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 30231744)

  • 81. How Often Are Drugs Made Available Under the Food and Drug Administration's Expanded Access Process Approved?
    McKee AE; Markon AO; Chan-Tack KM; Lurie P
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S136-S142. PubMed ID: 28921646
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Hearing on RU486 is held as test case fails to alter FDA's "import ban".
    Wash Memo Alan Guttmacher Inst; 1992 Jul; (12):2-3. PubMed ID: 12344814
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
    Harapanhalli RS
    Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
    [TBL] [Abstract][Full Text] [Related]  

  • 84. FDA recognition of consensus standards in the premarket notification program.
    Marlowe DE; Phillips PJ
    Biomed Instrum Technol; 1998; 32(3):301-4. PubMed ID: 9619259
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Advancing pharmaceutical quality: An overview of science and research in the U.S. FDA's Office of Pharmaceutical Quality.
    Fisher AC; Lee SL; Harris DP; Buhse L; Kozlowski S; Yu L; Kopcha M; Woodcock J
    Int J Pharm; 2016 Dec; 515(1-2):390-402. PubMed ID: 27773853
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Approval times for new drugs: does the source of funding for FDA staff matter?
    Carpenter D; Chernew M; Smith DG; Fendrick AM
    Health Aff (Millwood); 2003; Suppl Web Exclusives():W3-618-24. PubMed ID: 15506165
    [TBL] [Abstract][Full Text] [Related]  

  • 87. FDA use of international standards in the premarket review process.
    Rechen E; Barth DJ; Marlowe D; Kroger L
    Biomed Instrum Technol; 1998; 32(5):518-26. PubMed ID: 9800008
    [TBL] [Abstract][Full Text] [Related]  

  • 88. United States Food and Drug Administration Advisory Committee outcomes and agency approval analysis from 2010 to 2015.
    McCormack Z
    J Am Pharm Assoc (2003); 2018; 58(5):530-533. PubMed ID: 30005816
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Clinical research strategies in biotechnology.
    Vincent-Gattis M; Webb C; Foote M
    Biotechnol Annu Rev; 2000; 5():259-67. PubMed ID: 10875003
    [TBL] [Abstract][Full Text] [Related]  

  • 90. A guide to appeals within the English legal system.
    Hodgson J
    Br J Nurs; 2010 Jan 14-27; 19(1):48-50. PubMed ID: 20081713
    [TBL] [Abstract][Full Text] [Related]  

  • 91. International Conference on Harmonisation; Electronic Transmission of Postmarket Individual Case Safety Reports for Drugs and Biologics, Excluding Vaccines; Availability of Food and Drug Administration Regional Implementation Specifications for ICH E2B(R3) Reporting to the Food and Drug Administration Adverse Event Reporting System. Notice of Availability.
    Food and Drug Administration, HHS
    Fed Regist; 2016 Jun; 81(121):40890-1. PubMed ID: 27373012
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Medicare program; application of certain appeals provisions to the Medicare prescription drug appeals process. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2009 Dec; 74(235):65339-78. PubMed ID: 20169677
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Gaps and challenges in nonclinical assessments of pharmaceuticals: An FDA/CDER perspective on considerations for development of new approach methodologies.
    Avila AM; Bebenek I; Mendrick DL; Peretz J; Yao J; Brown PC
    Regul Toxicol Pharmacol; 2023 Mar; 139():105345. PubMed ID: 36746323
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Leveraging the Value of CDISC SEND Data Sets for Cross-Study Analysis: Incidence of Microscopic Findings in Control Animals.
    Carfagna MA; Anderson J; Eley C; Fukushima T; Horvath J; Houser W; Larsen B; Page T; Russo D; Sloan C; Snyder K; Thompson R; Ullmann G; Whittaker M
    Chem Res Toxicol; 2021 Feb; 34(2):483-494. PubMed ID: 33325690
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Characteristics of Successful and Unsuccessful Appeals Against Conviction for Child Sexual Abuse.
    Mills S; Sharman SJ
    Psychiatr Psychol Law; 2017; 24(5):655-669. PubMed ID: 31983980
    [TBL] [Abstract][Full Text] [Related]  

  • 96. FDA Oncology Center of Excellence Crowdsourcing Initiative: Outreach to the Scientific Community to Identify Research Questions for Pooled Analyses of Oncology Clinical Trial Data.
    Schneider JA; Eckstein J; Goldberg KB; Ascione MC; Bailey T; Taylor K; Coffey AM; Satchi D; Philips H; Sridhara R; Nair A; Pazdur R; Theoret MR
    Clin Cancer Res; 2023 Aug; 29(16):2964-2972. PubMed ID: 37011149
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Opportunities and challenges for applying model-informed drug development approaches to gene therapies.
    Belov A; Schultz K; Forshee R; Tegenge MA
    CPT Pharmacometrics Syst Pharmacol; 2021 Apr; 10(4):286-290. PubMed ID: 33608998
    [TBL] [Abstract][Full Text] [Related]  

  • 98. FDA's Janet Woodcock Riding High: CDER Director Wins "Wows" Amid Agency Woes.
    Barlas S
    P T; 2008 Jul; 33(7):396-7. PubMed ID: 19750117
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Salmonella Surveillance by the Food and Drug Administration: A Review 1974-1985.
    Wagner DE; McLAUGHLIN S
    J Food Prot; 1986 Sep; 49(9):734-738. PubMed ID: 30959674
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Exploring the Sequencing Effects of Fear-Hope Appeals on Promoting MMR Vaccination.
    Lu H; Yuan S
    Health Commun; 2023 Oct; 38(10):2132-2140. PubMed ID: 35341405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.